BCL2 and leukemia: To investigate the underlying mechanism of how venetoclax enhances the sensitivity of leukemia cells to sorafenib, we conducted single-cell sequencing analysis and found that the expression level of BCL2 was higher in the sorafenib-resistant group (SF-res group) than in the SF-unrelated and SF-sens groups (Figure 6a).